Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report

• DOI: 10.1016/j.gore.2023.101205
• Publication Date: 2023-05-24T01:13:15Z
• Authors: Motoki Matsuura; Kazuma Yorozu; Sachiko Nagao; Shoko Kurokawa; Masato Tamate; Taishi Akimoto; Tsuyoshi Saito
• Keywords: Eribulin; Pazopanib

Uterine leiomyosarcoma (LMS) is a gynecological malignancy with an extremely poor prognosis. Multiple new therapeutic agents, including pazopanib, trabectedin, and eribulin, have been clinically applied to treat uterine LMS, their effects are expected. We encountered one patient advanced recurrent LMS who achieved partial response four-year treatment eribulin. A 31-year-old woman was diagnosed stage 2B LMS. After the first recurrence, Gemcitabine, Docetaxel (GD) therapy administered, complete (CR) achieved. However, 2 years 10 months later, recurrence occurred at vaginal cuff, GD doxorubicin hydrochloride were resulting in CR. Five she experienced another same location treated To date, 53 courses of eribulin administered currently ongoing. Maintaining low neutrophil-to-lymphocyte ratio platelet-to lymphocyte this manner considered be reasons why continues effective. rare case which for longest period time, produced observable effect